FDMT
4D Molecular Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$11.09+0.91%
Price as of Jul 20, 2026
FDMT financials
4D Molecular Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $85.2M | $37.0K | $20.7M | $3.1M |
| Cost of revenue | $7.6M | $141.3M | $97.1M | $80.3M |
| Gross profit | $77.6M | -$141.3M | -$76.4M | -$77.1M |
| Operating expenses | $237.1M | $46.6M | $36.5M | $32.9M |
| Operating income | -$159.5M | -$187.8M | -$112.9M | -$110.0M |
| Net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M |
| EBITDA | -$132.5M | -$154.2M | -$96.6M | -$105.1M |
| Basic EPS | $-2.42 | $-2.98 | $-2.58 | $-3.12 |
| Diluted EPS | $-2.42 | $-2.98 | $-2.58 | $-3.12 |
| Balance sheet | ||||
| Cash & equivalents | $60.2M | $149.3M | $249.1M | $52.4M |
| Total assets | $566.7M | $560.4M | $339.9M | $261.8M |
| Total liabilities | $61.0M | $49.8M | $32.1M | $30.5M |
| Stockholders’ equity | $505.7M | $510.6M | $307.8M | $231.3M |
| Total debt | $21.4M | $24.6M | $14.7M | $16.1M |
| Net debt | -$38.8M | -$124.7M | -$234.4M | -$36.2M |
| Cash flow | ||||
| Operating cash flow | -$109.1M | -$134.6M | -$75.8M | -$86.7M |
| Capital expenditure | -$536.0K | -$3.8M | -$2.8M | -$11.5M |
| Free cash flow | -$109.1M | -$138.4M | -$78.6M | -$98.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |